Clarkston Capital Partners LLC Increases Stake in Johnson & Johnson $JNJ

Key Points

• Clarkston Capital Partners LLC increased its stake in Johnson & Johnson by 2.5%, owning a total of 124,377 shares valued at approximately $20.6 million after purchasing an additional 3,064 shares.
• Several research analysts have raised their price targets for Johnson & Johnson, with UBS Group increasing theirs from $180 to $190 and Bank of America from $161 to $175, maintaining generally positive ratings.
• Johnson & Johnson announced a quarterly dividend of $1.30, which will be paid to stockholders on September 9, with a dividend yield of 2.9%.

Clarkston Capital Partners LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 124,377 shares of the company's stock after purchasing an additional 3,064 shares during the period. Clarkston Capital Partners LLC's holdings in Johnson & Johnson were worth $20,627,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in JNJ. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at $47,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the 1st quarter valued at $49,000. Capital A Wealth Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at $50,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson during the 1st quarter valued at $52,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. UBS Group increased their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Bank of America increased their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Stock Performance

JNJ opened at $178.5890 on Thursday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $430.10 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 2.26 and a beta of 0.41. The company's 50 day moving average is $162.59 and its 200 day moving average is $158.87. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $180.61.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.